NFE2L2
Nuclear factor erythroid 2-related factor 2
As of the edition of 20 October 2026, NFE2L2 (nuclear factor erythroid 2-related factor 2, UniProt Q16236) has 4 drugs tested at it and 5 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16236
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 23
- Disease areas
- Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Hormones; Cancer; Inherited and neonatal; Nervous system; Lungs and airways
- Registered trials of its drugs
- 62
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bardoxolone methyl | Stopped | Phase 3 | none listed |
| Omaveloxolone | Marketed | Phase 3 | Ends 2033 |
| Oltipraz | Went quiet | Phase 3 | none listed |
| VVD-130037 | Active | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Biogen | Route B |
| PharmaKing | Route A |
| HK inno.N | Route A |
The other 2 companies at NFE2L2
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at NFE2L2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.